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Macaques were immunized with SF162 Env-based gp140 immunogens and challenged simultaneously with the CCR5-tropic homologous
SHIVSF162P4 and the CXCR4-tropic heterologous SHIVSF33A viruses. Both mock-immunized and immunized animals became dually infected.
Prior immunization preferentially reduced the viral replication of the homologous virus during primary infection but the relative replication of the
two coinfecting viruses during chronic infection was unaffected by prior immunization, despite the fact that five of six immunized animals
maintained a significantly lower overall viral replication that the control animals. Neutralizing antibodies participated in controlling the
replication of SHIVSF162P4, but not that of SHIVSF33A. Dual infection resulted in the emergence and predominance within the circulating CCR5
virus pool, of a variant with a distinct neutralization phenotype. The signature of this variant was the presence of three amino acid changes in
gp120, two of which were located in the receptor and coreceptor binding sites. Also, a significant fraction of the viruses circulating in the blood,
as early as two weeks post-infection, was recombinants and prior immunization did not prevent their emergence. These findings provide new
insights into the dynamic interaction of CCR5- and CXCR4-tropic HIV isolates that are potentially relevant in better understanding HIV-mediated
pathogenesis.
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HIV envelope-based immunogens have so far been ineffec-
tive in eliciting potent cross-reactive neutralizing antibodies
(NAbs), in particular against heterologous primary HIV isolates
(Bower et al., 2004; Earl et al., 2001; Gao et al., 2005; Garrity et
al., 1997; Gzyl et al., 2004; Haigwood et al., 1992, 1990;
Hanson, 1994; Kim et al., 2003; Mascola et al., 1996; VanCott⁎ Corresponding author. Seattle Biomedical Research Institute, 307 Westlake
Avenue North, Seattle, WA 98109, USA. Fax: +1 206 256 7229.
E-mail address: leo.stamatatos@sbri.org (L. Stamatatos).
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doi:10.1016/j.virol.2006.07.026et al., 1997; Yang et al., 2004a). Although recent improvements
have been made in the design of soluble HIV oligomeric
envelope immunogens (gp140s) to elicit cross-reactive NAbs,
the antibody responses they elicit are still weak in breadth and
potency (Barnett et al., 2001; Dong et al., 2003; Grundner et al.,
2005; Yang et al., 2001, 2004b). Therefore, it is anticipated that
currently available HIV Env immunogens will fail to protect a
vaccinee from infection by isolates expressing envelope
glycoproteins that are heterologous to the immunogen. Even
more alarming is the fact that it is very difficult, in the macaque/
SIV or macaque/SHIV models, to even elicit by Env-based
immunization protocols sterilizing immunity against viruses
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Env immunogen (Amara et al., 2001, 2002b; Buckner et al.,
2004; Davis et al., 2000; Doria-Rose et al., 2003; Earl et al.,
2002; Fultz et al., 2003; Horton et al., 2002; Hu et al., 1992;
Johnson et al., 2005; Lifson et al., 2004; Murphy et al., 2000;
Ourmanov et al., 2000; Patterson et al., 2004, 2002; Polacino
et al., 1999a,b,c; Ramsburg et al., 2004; Robinson et al.,
1999; Rose et al., 2001; Shiver et al., 2002; Willey et al.,
2003; Zhao et al., 2003). However, priming by immunization
of anti-HIV Env-specific B cell responses does offer to
immunized macaques protection from disease development
when the challenge virus expresses an envelope glycoprotein
that is homologous to the immunogen and, in general, the
inclusion of the viral envelope glycoprotein in the vaccine
formulation enhances the protective potential of the antiviral
responses elicited following infection (Amara et al., 2002a;
Letvin et al., 2004).
All the above immunization/challenge animal studies were
conducted with a single virus as a challenge. In the present study,
we examined how the replication of two viruses, one expressing
an envelope glycoprotein that is homologous to the Env
immunogen and a second virus expressing an envelope
glycoprotein that is heterologous to the immunogen, will be
affected in a dually infected host, by the presence or absence of
pre-existing (vaccine-elicited) neutralizing antibody responses
that target preferentially one of the two infecting viruses. To this
end, following immunization of macaques with HIV-1 SF162-
derived Env gp140 immunogens, the animals were simulta-
neously exposed to two SHIVs: SHIVSF162P4, expressing an
envelope that is homologous to our immunogens and SHIVSF33A
expressing an envelope that is heterologous to our immunogens.
These viruses share a common SIVmac239 genetic backbone
(they differ in Env by approximately 20%) and replicate to high
titers in macaques when inoculated individually (Harouse et al.,
1998). Also, SHIVSF33A and a virus related to SHIVSF162P4,
termed SHIVSF162P3, can both replicate to high titers in dually
infected macaques (Harouse et al., 2003), in the absence of pre-
existing anti-SHIV immunity.
Our results indicate that immunization with our SF162-
derived gp140 Env constructs did not offer sterilizing
immunity during intravenous challenge, but significantly
reduced the early replication of the homologous, but not the
heterologous, virus during acute infection. Immunization also
resulted in a significant reduction in the overall plasma
viremia, in five of six macaques, during chronic infection
without affecting the relative replication of the two coinfecting
viruses. Nor did immunization prevent the emergence of
recombinant (within the env region) viruses. However, the
presence of the X4-tropic virus resulted in the emergence and
persistence of a R5 clone that is a minor species in the
SHIVSF162P4 inoculum, indicating that during coinfection with
R5- and X4-tropic viruses a complex and dynamic interaction
between the two viruses takes place at the cellular level.
Although our studies were conducted in the SHIV rhesus
macaque animal model, we believe that they are pertinent to
infection of humans by HIV and provide information that is
relevant to HIV-mediated pathogenesis.Results
Development of antienvelope binding antibodies during
immunization
During the DNA phase of immunization anti-Env antibody
responses were detectable in only three animals, L170 and
L667, in the ΔV2gp140 immunized group, and I658, in the
GM154gp140 immunized group (Fig. 1A). As we and others
previously reported, the binding anti-Env antibody titers were
weak, transient and decreased to undetectable levels within
2–3 months following the third DNA immunization (Buckner
et al., 2004; Cherpelis et al., 2001). However, a boosting of
binding anti-Env antibody titers was recorded 2–4 weeks
following immunization with the recombinant envelope gp140
proteins. These titers decreased rapidly (by half or more)
during the subsequent 2 weeks of observation. Animal H266,
immunized with SF162gp140, had the lowest binding anti-Env
antibody titers.
Neutralization potential of vaccine-elicited serum antibodies
(A)Homologous NAbs: During the DNA phase of immuniza-
tion, anti-SHIVSF162P4 neutralizing antibody responses were
undetectable, as previously reported (Barnett et al., 2001;
Buckner et al., 2004; Srivastava et al., 2003b). Following
recombinant gp140 protein boost, all immunized animals
(irrespective of the Env gp140 immunogen) developed potent
but comparable anti-SHIVSF162P4 NAb titers (Fig. 1B, top two
panels). Animal H266 had the lowest titers of NAbs, most likely
because it developed the lowest titers of anti-HIV Env antibodies
in general (see above). The homologous neutralizing antibody
titers decreased in all animals (to varying degrees) over the next
2weeks.We also evaluated the neutralizing potency of these sera
against HIV-1 SF162 (Fig. 1B, bottom two panels). As expected
(SHIVSF162P4 and HIV-1 SF162 express envelope glycoproteins
very similar in amino acid composition) all animals elicited
potent anti-HIV-1 SF162 NAbs. Differences in IC50 between
HIV-1 SF162 and SHIVSF162P4 most likely are due to the fact
that during neutralization, replication competent virus grown in
PBMC was used in the case of SHIVSF162P4, while single round
competent virus generated by 293T cell transfection was used in
the case of HIV-1 SF162. (B) Heterologous neutralizing
antibodies: we were also interested in examining whether the
three gp140 Env immunogens elicited NAbs against hetero-
logous HIV-1 isolates. To this end, sera collected 2 weeks
following immunization with recombinant gp140 were evalu-
ated against single round competent viruses expressing the
envelope glycoproteins of 33A, HxB2, 89.6, JRFL, ADA, and
YU2 (Table 1). The two animals immunized with SF162gp140
did not elicit anti-89.6 and anti-HxB2 Nabs. In contrast, all
animals immunized with the modified ΔV2gp140 or
GM154gp140 immunogens elicited anti-89.6 and anti-HxB2
NAbs. However, all other isolates tested here were resistant to
neutralization. Therefore, these two envelopemodifications alter
the immunogenic properties of SF162gp140 proteins (as we
previously described in the case of ΔV2gp140 (64)), but not in
Fig. 1. Antibody responses during immunization. (A) Relative end-point anti-Env antibody titers and (B) neutralizing antibody titers against SHIVSF162P4 (top two
panels) and HIV-1 SF162 (bottom two panels) were determined as described in the Materials and methods section. Neutralizing activity was evaluated at 2 and 4 weeks
post-recombinant gp140 protein boosting.
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neutralize heterologous HIV-1 isolates.
Plasma viremia in macaques dually infected with SHIVSF162P4
and SHIVSF33A
We previously reported that in naïve rhesus macaques,
SHIVSF162P4 replicates very efficiently, reaching acute plasma
viremia levels in the order of 107 to 108 viral RNA copies per ml
(Buckner et al., 2004; Cherpelis et al., 2001). Similar levels of
replication have been reported in SHIVSF33A-infected macaques
(Harouse et al., 2003). In this study, the simultaneous inoculationTable 1
Neutralization of heterologous HIV-1 isolates by immune sera
Animal Immunogen Isolates
33A HxB2 89.6 JRFL ADA YU2 MuLV
H266 SF162gp140 (–) 10 (–) (–) (–) (–) (–)
I375 SF162gp140 (–) (–) (–) (–) (–) (–) (–)
I646 GM154gp140 (–) 30 10 (–) (–) (–) (–)
I658 GM154gp140 (–) 100 10 (–) (–) (–) (–)
L170 ΔV2gp140 (–) 30 30 (–) (–) (–) (–)
L667 ΔV2gp140 (–) 30 15 (–) (–) (–) (–)
Neutralization was recorded as described in the Materials and methods section
using single round competent virions expressing the indicated envelopes. The
values indicate the serum dilution at which 50% neutralization was recorded
with sera collected 2 weeks following the recombinant envelope gp140
immunization against sera collected prior to immunization. (–): 50%
neutralization was not recorded at the lowest serum dilution tested (1:10).of mock-immunized rhesus macaques with SHIVSF162P4 and
SHIVSF33A (100 TCID50 each) resulted in peak plasma viremia
of 106–108 RNA copies/ml (Fig. 2A). No differences in acute
plasma viremia (day 14) levels were recorded between themock-
immunized and immunized animals (P=0.22). Subsequently,
the plasma viremia levels in the mock-immunized animals
decreased and then fluctuated during chronic infection between
2×104–105 RNA copies/ml. The plasma viremia in five of the
six immunized animals decreased to levels that were signifi-
cantly lower (P=0.026, days 203–267) than those recorded in
the mock-immunized animals. In one immunized animal (I375)
plasma viremia became undetectable. In the sixth immunized
animal, H266, the levels of plasma viremia were higher than in
the mock-immunized animals and gradually increased to
approximately 108 RNA copies per ml. Such an unusually
high level of viremia had not been previously observed in
macaques infected with SHIVSF33A or SHIVSF162P4 (or the
related SHIVSF162P3 virus) (Buckner et al., 2004; Harouse et al.,
2003; Harouse et al., 1999). This animal developed AIDS and
was euthanized 239 days post-infection.
CD4+ T lymphocyte numbers during dual infection
Within 2 weeks after challenge, a reduction in the numbers of
peripheral CD4+ T lymphocytes occurred in both mock-
immunized and immunized animals (Fig. 2B). This reduction
is most likely due to infection with SHIVSF33A since the R5-
tropic SHIVSF162P4 does not induce such a significant loss of
Fig. 2. Plasma viremia and CD4+ T lymphocyte numbers. (A) Plasma viremia was monitored by the b-DNA assay (dashed line indicates the limit of detection 125
RNA copies per ml). (B) CD4+ T lymphocyte numbers per μl of blood were determined as described in the Materials and methods section.
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(Buckner et al., 2004). The CD4+ T cell loss was sustained in
the two mock-immunized animals (M030 and R044) and in the
SF162gp140-immunized animal H266 that did not control
plasma viremia (Fig. 2A). In the remaining immunized animals
a rebound of CD4+ Tcell numbers occurred. With the exception
of immunized animal I646 (GM154gp140-immunized), these
numbers remained stable throughout the period of observation.
The animals were euthanized at different times (day 203:
L667, I646 and I658; day 239: H266; day 246: M030; day 407:
R044, L170 and I375) during chronic infection in order to
determine the CD4+ T cell numbers in various lymph nodes
(axillary, inguinal, mesenteric, bronchial, and iliac) as well as
the spleen. A severe CD4+ T lymphocyte depletion was
recorded in all these tissues in all animals. CD4+ T lymphocytes
were either absent from these tissues or constituted less than 4%
of all CD3+ T lymphocytes present. However, with the
exception of animal H266 and I646, both of which experienced
a sustained loss of peripheral CD4+ T lymphocytes, the
immunized animals in this study had not yet developed clinical
signs of AIDS at the time of euthanasia.
Relative ratio of SHIVSF162P4, SHIVSF33A, and recombinant
viruses in the blood
Viral RNA was isolated from plasma collected from each
macaque during acute viremia (day 14 post-infection), and at
two time points during chronic infection, at day 99, and from the
day the animal was euthanized (between 203 and 407 days post-
infection). The C2V5 region of gp120 was amplified and the
PCR fragments were cloned and sequenced or further amplified
for use in heteroduplex mobility assays (HMA) to determine the
relative ratio of SHIVSF162P4 and SHIVSF33A viruses. At least
twenty individual clones from each time point were examined.
In addition, several of the clones that were analyzed by HMA
were also sequenced for confirmation.Our results indicate that all animals were infected with both
SHIVSF162P4 and SHIVSF33A (Table 2). During acute infection
(day 14), the two viruses replicated differently in the two mock-
immunized animals. In animal M030, SHIVSF162P4 was
predominant (70%). In contrast, in animal R044, SHIVSF33A
was predominant (63%) at this time. These results are in
agreement with those reported by others (Harouse et al., 2003)
that these two R5- and X4-tropic SHIVs are equally efficient in
coinfecting and coreplicating in macaques during intravenously
challenge. Following clearance of acute viremia (day 99),
SHIVSF162P4 predominated over SHIVSF33A in the blood of both
mock-immunized animals, consistent with previous reports of
R5- and X4-tropic dually challenged naïve animals (Harouse et
al., 2003). The relative proportion of SHIVSF162P4 in the mock-
immunized animals was 80% and 95% (M030 and R044
animals, respectively) at that point.
Recombinant (in the env region) viruses were undetectable
in the periphery of the mock-immunized animals during acute
infection. Such recombinants were detectable however at 99
days post-infection in animal M030 (15% of viral species).
In the immunized groups SHIVSF162P4 replication was
significantly reduced (P=0.022) during acute infection (day 14),
but not that of SHIVSF33A (P=0.37), as compared to the
mock-immunized macaques. Following acute infection, how-
ever, at day 99, a predominance of SHIVSF162P4 was recorded
in all the immunized animals, similar to what occurred in the
mock-immunized animals. At day 99, SHIVSF162P4 represented
95% (I658), 60% (H266), 50% (I646), and 100% (I375, L170
and L667) of all the viral species present in the periphery of
the immunized animals. Although the relative proportion of
SHIVSF162P4 increased in the immunized animals between
days 14 and 99, the absolute plasma viremia was 11- to 104-fold
lower than during peak acute infection in these animals.
Interestingly, recombinant viral species were present in five of
the six immunized animals (representing 5–10% of the total
viral pool) as early as 14 days post-infection. At day 99 post-
Table 2
Plasma viremia and relative ratio of circulating viruses during acute and chronic infection
Macaque DPI a Copies
RNA/
ml
Percent of clones b Estimated Relative copies RNA/ml c
P4 33A Recom. P4 33A Recom.
M030 (Mock) 14 1.3×108 70 30 ND 9.1×107 3.9×107 –
99 2.3×104 80 5 15 1.8×104 1200 3400
246 1.5×105 53 11 37 8.0×104 1.6×104 5.6×104
R044 (Mock) 14 3.6×107 37 63 ND 1.3×107 2.3×107 –
99 1.4×104 95 5 ND 1.3×104 700 –
457 7.6×104 45 30 25 3.4×104 2.3×104 1.9×104
H266 (SF162) 14 3.5×107 10 85 5 3.5×106 3.0×107 1.8×106
99 5.3×105 60 ND 40 3.2×105 – 2.1×105
239 9.0×107 ND 12 88 – 1.1×107 7.9×107
I375 (SF162) 14 5.5×106 75 15 10 4.1×106 8.2×105 5.5×105
99 270 100 ND ND 270 – –
457 130 58 42 ND 75 55 –
I646 (GM154) 14 6.4×106 5 85 10 3.2×105 5.4×106 6.4×105
99 9400 50 50 ND 4700 4700 –
203 1600 78 22 ND 1250 350 –
I658 (GM154) 14 1.3×107 5 90 5 6.5×105 1.2×107 6.5×105
99 2200 95 5 ND 2100 100 –
203 1100 50 20 30 550 220 330
L170 (ΔV2) 14 1.5×107 5 95 ND 7.5×105 1.4×107 –
99 1.4×104 100 ND ND 1.4×104 – –
457 7500 ND 84 16 – 6300 1200
L667 (ΔV2) 14 6.2×107 10 85 5 6.2×106 5.3×107 3.1×106
99 550 100 ND ND 550 – –
203 1300 33 67 ND 430 870 –
ND or (–): not detected.
a Days post-infection.
b Determined by HMA and sequencing analysis.
c Based on the total RNA copies per ml and the percent of SHIVSF162P4 (P4), SHIVSF33A (33A), or recombinant (Recom.) clones.
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animal H266 (40% of the total viral species).
At later times during chronic infection (days 203–407), a
mixture of viruses was present in the blood of all animals. The
mock-immunized animals contained SHIVSF162P4, SHIVSF33A
and recombinant species, with SHIVSF162P4 being the pre-
dominant virus (between 45% and 53% of the total viral
species). Even though these percentages are lower than those
recorded at day 99, the absolute number of SHIVSF162P4 viral
particles increased during that period (Table 2). Only one
immunized animal, I658, had all three viral species present
(SHIVSF162P4 50%, SHIVSF33A 20%, and recombinant 30%) at
these later stages of infection. In three other immunized animals
(I375, L667, and I646) the two challenge viruses were detected
(with SHIVSF162P4 present at 33–75% of the total viral
population) but not the recombinant virus. In the remaining
two immunized macaques (L170 and H266) only SHIVSF33A
and recombinant virus were detectable, not SHIVSF162P4. L170
contained 84% SHIVSF33A and 16% recombinant species, while
H266 contained a majority of recombinants (88%) with
SHIVSF33A making up the rest of the viral species (12%).
Emergence of a specific SHIVSF162P4 variant
In mock-immunized macaques infected with only
SHIVSF162P4, envelope changes start to gradually emerge by
70 days post-infection, concomitant with the appearance ofNAbs (Stamatatos, L., L.G. Gines, C.J. Saunders, L. Vojtech, I.
Srivastava, S.W. Barnett, J.T. Safrit, C. Buckener, W. Blay, N.
Haigwood, and R. McCaffrey Successful containment of viral
replication in macaques infected with an R5-tropic SHIV
depends on the early development of antienvelope antibodies.
21st Annual Symposium on Nonhuman Primate Models for
AIDS, 2003) (and data not shown). To examine whether the
envelope of SHIVSF162P4 evolved in a similar manner in the
presence of the competing SHIVSF33A virus, and also to
examine whether and how the envelope of SHIVSF33A evolved
in parallel, we performed longitudinal sequence analysis of the
plasma virus envelope (C2V5). This envelope region of all
SHIVSF33A viral clones sequenced throughout the course of
infection was very similar to that found in the inoculating
SHIVSF33A viral stock swarm (data not shown). However, in the
case of SHIVSF162P4, in all animals, irrespective of whether they
were previously immunized or not, a specific envelope variant
emerged shortly after infection and predominated thereafter.
The signature of this envelope variant consisted of three
mutations as compared to the consensus challenge SHIVSF162P4
C2V5 sequence (Fig. 3). These mutations were located in the
C3 (S361P), V4 (Q385R) and C4 (Y425H) regions of gp120.
This triple mutant (termed PRH) was detected as early as day
seven post-infection in the immunized animals L170 and I658
(data not shown). By day 14, this triple variant was established
in both the mock-immunized and immunized animals, with the
exception of H266, irrespective of the relative ratio of the R5
Fig. 3. Emergence of the PRH mutant in the dually infected animals. The C2 to V5 region of the gp120 glycoprotein was sequenced longitudinally from all animals.
The positions of the three amino acid changes: S to P, Q to R, and Y to H are indicated by shaded boxes. The number of clones containing this sequence out of the total
SHIVSF162P4 clones sequenced is shown on the right of each sequence. None: only SHIVSF33A (and/or recombinant) virus was detected.
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comprised the majority of the SHIVSF162P4 species in all
animals. Subsequently, the PRH variant was detected in four of
the six animals in which SHIVSF162P4 species were present. In
the other two animals (R044 and I658) the consensus SHIV-
SF162P4 virus was detectable, but not the PRH variant. In
macaques H266 and L170 only the X4-tropic virus (and
recombinants, see below) was detectable at that time of
infection. Interestingly, the PRH variant did not appear to
develop quasispecies character as very few clones included
additional mutations in the C2V5 region (Fig. 3).
Phenotypic analysis of the PRH virus
The PRH variant is a minor species in the SHIVSF162P4
inoculum (approximately 3%) (data not shown). Its selection in
SHIVSF162P4-infected macaques was never recorded previously.
However, this variant was selected for in both the mock-
immunized and immunized animals studied here. Since anti-Env
antibody responses were not detectable in the mock-immunized
animals during the first 10 weeks of infection (data not shown),
the emergence of the PRH variant appears to be independent of
the presence of anti-Env antibody responses and most likely a
consequence of the simultaneous infection by SHIVSF33A.The S361P change is located in the CD4 binding site; the
Q385R is in the outer domain of gp120; and the Y425H change
is close to residues involved in CCR5 recognition (Kwong et al.,
1998). Specifically, S365 of HxBc2, which is analogous to S361
in SF162, was shown to participate in backbone–backbone
contacts with CD4 (Kwong et al., 1998). An amino acid change
from serine to proline could significantly alter these contacts
and/or induce local conformational changes in this region of the
CD4 binding site. Mutation of this analogous serine in NL4-3
was shown to impair viral infectivity (Otto et al., 2003).
Mutation of a tyrosine residue on HIV-1 YU2 gp120, that is
analogous to Y425 of SHIVSF162P4, reduced CCR5 binding
(Rizzuto and Sodroski, 2000; Rizzuto et al., 1998). We were
therefore interested in determining whether the PRH variant
displayed a different receptor/coreceptor interaction to that of
SHIVSF162P4, which is CD4 and CCR5 dependent (Harouse et
al., 1999), offering a replication advantage to the PRH virus over
SHIVSF162P4. We introduced these three mutations into the
backbone of the SF162 envelope gp160 to investigate this
possibility. Single round competent viruses expressing the
SF162 Env with the PRH mutations were incubated with cells
expressing CD4 and CCR5, CD4 and CXCR4, CCR5 alone, or
CXCR4 alone and the extent of viral entry was monitored. Our
results indicate that the PRH mutations do not affect Env
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mediates virus-cell fusion with the same efficiency as the
parental SF162 envelope) and do not alter the utilization of
CD4, CCR5, and CXCR4 by the envelope (data not shown).
Development of neutralizing antibodies following infection
As mentioned above, anti-SHIVSF162P4 but not anti-
SHIVSF33A NAbs were developed during immunization (Fig.
1 and Table 1). We were interested to examine whether anti-
SHIVSF33A NAbs developed following infection; whether prior
immunization with SF162 Env-derived immunogens affected
the development of anti-SHIVSF33A NAbs; and whether the
NAbs developed during infection neutralized the PRH variant.
During these neutralization assays we used pseudoviruses
expressing the SF162 envelope glycoprotein, since HIV-1
SF162 and SHIVSF162P4 express the same envelope and have
very similar neutralization profiles (Fig. 1B). A cloned enve-
lope gp160 from SHIVSF33A (provided by Dr. C. Cheng-
Mayer, ADARC) was used to generate single round competent
virions expressing the SHIVSF33A envelope. The PRH
mutations were introduced into the SF162 gp160 envelope
glycoprotein.Fig. 4. Neutralization susceptibility by serum antibodies developed during coinfectio
neutralization susceptibility of SF162 (black symbols), PRH (red symbols) and 33A (b
animals was determined as described in the Materials and methods section.The mock-immunized animals did not develop potent anti-
SHIVSF33A NAbs during the period of observation, but both
developed high titers of anti-PRH NAbs (Fig. 4). Interestingly,
although animal R044 developed strong anti-SF162 NAbs,
animal M030 developed very weak anti-SF162 NAbs. In
contrast, all the immunized animals developed anti-PRH NAbs
while maintaining the production of anti-SF162 NAbs. Anti-
SHIVSF33A NAbs were generated only in some immunized
animals (H266, I375, L170, and I646) and only during the late
stages of the observation period. Anti-SHIVSF33A NAbs were
undetectable in the immunized animals at 99 days post-
infection. This suggests that NAbs had very little to do with
the extent of replication of SHIVSF33A during the first 99 days of
infection in these dually infected animals. Interestingly, the
PRH variant was several fold more susceptible to neutralization
than SF162 to neutralization by serum antibodies collected at all
stages of infection.
Discussion
Previously, we showed that immunization of macaques with
gp140 Env constructs derived from the HIV-1 SF162 envelope
glycoprotein resulted in the long-term control of viraln. The PRH mutations were introduced on the SF162 Env background and the
lue symbols) to serum antibodies developed longitudinally in the dually infected
Fig. 4 (continued).
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envelope that is homologous to the immunogens used (Buckner
et al., 2004). In this study, we wished to determine if there
would be similar control of viral replication when macaques
immunized with SF162 envelope-based gp140 immunogens,
were simultaneously exposed to two viruses: one (SHIVSF162P4)
that expresses an envelope homologous to the immunogens and
another virus (SHIVSF33A) that expresses an envelope which is
heterologous to the immunogens. To this end, we immunized
macaques with three different SF162-derived gp140 envelope
constructs (SF162gp140, ΔV2gp140, and GM154gp140) prior
to challenge with SHIVSF162P4 and SHIVSF33A and then
monitored longitudinally viral replication and evolution.
All three immunogens elicited potent homologous NAbs but
only the modified immunogens (ΔV2gp140 and GM154gp140)
elicited heterologous NAbs. However, these cross-reactive
neutralizing antibody responses were weak and very narrow
in breadth, targeting viruses that are considered to be easily
neutralizable. NAbs against the heterologous SHIVSF33A virus
were undetectable during immunization with the three gp140
immunogens evaluated here.
Following viral challenge the immunized animals had
indistinguishable peak plasma viral loads from the mock-
immunized animals. Similarly, no significant difference in the
RNA copies of SHIVSF33Awas detected at this time between themock-immunized and immunized animals. However, the early
reduction of the homologous SHIVSF162P4 virus in the
immunized animals suggests that the immune responses elicited
during immunization contributed to the initial control of this
virus, in accordance to our previous observations made during
single infection with SHIVSF162P4 (Buckner et al., 2004).
Following acute viremia (by day 99), five of the six
immunized macaques had lower overall viral loads than the
mock-immunized animals. At that point, the SHIVSF162P4 virus
predominated in the two mock-immunized and in 5/6
immunized animals. The predominance of SHIVSF162P4 over
SHIVSF33A following acute infection is consistent to previous
reports (Harouse et al., 2003) and appears to be unrelated to the
immune responses elicited during immunization. The predomi-
nance of the R5-tropic SHIVSF162P4 virus at this time could in
part be due to the reduction of CD4+ T lymphocytes from the
periphery, that occurred in all animals within 2 weeks post-
infection. Peripheral CD4+ T lymphocytes are the major targets
for the X4-tropic SHIVSF33A virus, while the R5-tropic
SHIVSF162P4 virus preferentially replicates in the GALT
associated CD4+ T lymphocytes (Harouse et al., 1999). With
the exception of animal H266, the immunized animals were able
to control viral replication (see Table 2) to levels that were
significantly lower than those recorded in the mock-immunized
animals during chronic infection. Additionally, the relative
146 B. Burke et al. / Virology 355 (2006) 138–151replication of the two viruses during chronic infection differed
from animal to animal most likely due to the fact that these are
out bread nature animals.
A consequence of dual or super infection is the emergence of
recombinant viruses (Esteves et al., 2003; Grisson et al., 2004;
Gundlach et al., 2000; Sabino et al., 1994). Recombinant viral
species (within the C2V5 envelope region) were present in both
mock and immunized animals. In certain cases (animals L667,
I646, and I375) recombinants were present early but not late in
infection. In other animals (M030, R044, and L170) recombi-
nant viral species appeared later during infection. These
observations are indicative of a dynamic viral replication, and
potential competition, of the various viral species present in
these animals, even though these viruses display distinct
coreceptor usage. The Env recombinant viruses we identified
here may not accurately represent the total recombinant viral
species present in these animals since recombination could have
occurred outside the env region of the viral genome. The
identification of such recombinants is not feasible since
SHIVSF162P4 and SHIVSF33A share the same genome outside
the env.
Interestingly, although anti-SHIVSF162P4 NAbs developed
early in the coinfected animals, anti-SHIVSF33A NAbs were
not developed until much later during infection, and only in a
few animals. Therefore, although NAbs most likely were
involved in regulating the replication of SHIVSF162P4, they did
not participate in regulating the replicative potential of
SHIVSF33A. We can speculate at this point that the reduction
in SHIVSF33A replication following primary infection was due
to either a reduction in available target cells, and/or to the
early emergence of anti-SHIVSF33A specific T cell responses.
The involvement of cell-mediated immunity in the relative
control of replication of the two coinfecting viruses merits
detailed investigation.
Since SHIVSF162P4 and SHIVSF33A utilize different cor-
eceptors and preferentially replicate in different anatomical
sites, why do recombinant viruses emerge so early after
infection? The coreceptor utilization of these viruses was
evaluated in vitro using established cell lines as target cells
(Harouse et al., 1999). These in vitro results may not
accurately predict what occurs in vivo. It is also conceivable
that in vivo, individual cells expressing both CCR5 and
CXCR4 become infected by the two viruses. It is also possible
that cells, some of which are infected with SHIVSF33A and
some by SHIVSF162P4, form syncytia. These possibilities could
lead to the emergence of recombinant viruses.
After infection a single viral clone (PRH) predominated the
SHIVSF162P4 viral pool in both the mock-immunized and
immunized animals. As this variant is detected early (7–14
days post-infection) in seven of eight macaques, including the
mock-immunized animals, it is unlikely to be the result of
antibody responses, as these responses were not detected until
much later in the mock-immunized animals (data not shown).
Because the PRH variant does not predominate during
SHIVSF162P4 single challenge studies, the emergence and the
predominance of the PRH virus in the dually infected animals
appears to be related to the presence of the coinfectingSHIVSF33A virus. Additionally, the PRH variant is highly
susceptible to neutralization by antibodies elicited during this
dual infection. It is difficult to find a rational explanation for
why a neutralization susceptible variant, such as PRH, would
emerge during infection, unless it has a replicative advantage
over the other viruses that circulate in these animals. So, it is
possible that PRH emerged as a result of competition at the
cellular level with the SHIVSF33A virus. The PRH mutations
are located at the C3, V4, and C4 regions of gp120. The
mutations in C3 (S361P) and C4 (Y425H) are located in
regions of the viral envelope glycoprotein that interact with
CD4 and possibly influence CCR5 binding, respectively
(Kuroda et al., 1998; Rizzuto and Sodroski, 2000). However,
the PRH mutations do not alter the CD4 and CCR5
dependence of the SF162 envelope. One caveat here is that
the PRH mutations were examined in the context of the SF162
Env. It is therefore possible that on the actual virus that
replicated in those animals, other mutations located outside the
C2V5 region, in combination with the PRH mutations,
conferred to the envelope a receptor/coreceptor recognition
phenotype that is distinct from that of SF162 Env or of the
SF162 Env with the PRH mutations. We did sequence the
entire gp120 and part of the extracellular region of gp41 from
three PRH clones from one animal and we did not record any
other major amino acid changes (data not shown). However,
sequencing and analysis of additional PRH full-length gp160
sequences are necessary to examine this possibility in more
detail. An additional possibility is that the PRH mutations
allow the virus to utilize coreceptor molecules other than
CCR5 (here we only examined the possibility that PRH can
utilize CXCR4 or not). This is something that also needs
further exploration. It would be interesting to test whether a
similar emergence of the PRH variant would occur when the
coinfecting virus is different than SHIVSF33A, for example,
SHIV89.6P (which also utilizes CXCR4) or SIVmac239
(which utilizes primarily CCR5). A previous study has
indicated a complex relationship in the relative replicative
properties of SHIV89.6P and SIVmac251 in dually infected
macaques (Wolinsky et al., 2004). In that study the
experimental reduction in the replication of the R5-tropic
virus resulted in a parallel increase in the replication of the X4
virus. However, in that study the potential emergence of
specific viral variants was not examined.
It could be argued that the experimental situation presented
here (i.e., coinfection by R5- and X4-tropic viruses) will not
occur frequently during natural HIV-1 infection. R5-tropic
HIV-1 viruses are those that predominantly establish infection
in naïve individuals. However, there is evidence of transmis-
sion of X4-tropic HIV-1 viruses (Cornelissen et al., 1995;
Groenink et al., 1991; Roos et al., 1992; Schuitemaker et al.,
1992; van't Wout et al., 1994) and there is evidence that
multiple variants can be transmitted simultaneously (Ritola et
al., 2004). The primary aim of this study was to examine how
immunization with our current gp140 Env immunogens would
affect the relative replication of coinfecting viruses. Based on
our results, we would anticipate that extensive recombination
between the infecting HIV-1 viruses will occur very soon after
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coreceptor molecules, and that immunization will not alter the
frequency of recombination. However, our immunogens
elicited NAbs against one of the two infecting viruses and it
would be interesting to examine whether similar observations
will be made if the immunogens elicit neutralizing antibody
responses against both viruses.
In summary, our studies indicate that until immunogens and
immunization strategies are designed that would elicit
sterilizing immunity against HIV, establishment of infection
by diverse isolates would be possible and recombination
among these isolates would occur early. Potentially, such
recombinants could affect the rate of progression to disease
and be transmissible, in which case future vaccines must
prevent their spread. Our studies also indicate that a complex
interaction may occur during HIV infection between CCR5-
tropic and CXCR4-tropic viruses and this interaction may
affect both the development of antiviral immune responses as
well as pathogenesis.
Materials and methods
Animals, immunogens and immunization protocol
Adult rhesus macaques of Indian origin were housed at the
Tulane National Primate Research Center. The immunogens
used in these studies were derived from the SF162 envelope.
Three related immunogens were used, SF162gp140,ΔV2gp140
and GM154gp140, which were generated by introducing stop
codon sequences upstream from the transmembrane region of
the SF162 (Stamatatos and Cheng-Mayer, 1998), SF162ΔV2
(Stamatatos and Cheng-Mayer, 1998) and GM154 envelopes
(Ly and Stamatatos, 2000), respectively. SF162ΔV2 was
derived from SF162, by deleting 30 out of the 40 amino acids
of the second hypervariable regions (V2 loop). GM154 was also
derived from SF162 by eliminating an N-linked glycosylation
site at the amino terminal side of the V2 loop (position 154)
which protects SF162 from antibody-mediated neutralization
(Ly and Stamatatos, 2000). DNA vectors expressing these three
immunogens were generated as we previously described
(Barnett et al., 2001).
The animals received three DNA immunizations at 4-week
intervals as we previously described in detail (Barnett et al.,
2001). Following a resting period of 40 weeks, the animals
received a fourth DNA immunization and at the same time
they were immunized with the corresponding purified
oligomeric gp140 protein, emulsified with the MF-59C
adjuvant. A total of 2 mg DNA in 1 ml of endotoxin-free
water was administered each time per animal. 1.6 mg was
administered intramuscularly at the quadriceps and 0.4 mg
were administered intradermally at two sites. A total of 0.1 mg
of protein in 0.5 ml total volume was administered
intramuscularly to the deltoids of each animal. Mock-
immunized animals received the ‘empty’ DNA vector and
the MF-59C adjuvant. The DNA vectors expressed the three
gp140 proteins with intact gp120-gp41 cleavage sites. In
contrast, this site was eliminated by mutagenesis from thecorresponding recombinant gp140 proteins (Srivastava et al.,
2003a).
Viral challenge
Four weeks following the last immunization, the animals
were challenged intravenously with 100 TCID50 of cell-free
SHIVSF162P4 virus (Harouse et al., 1999) and 100 TCID50 of
cell-free SHIVSF33A (Harouse et al., 1998). The SHIVSF162P4
and SHIVSF33A viruses were provided by Drs. Cheng-Mayer
and Harouse (ADARC) and were propagated in Dr. Stamata-
tos's laboratory once in PHA-activated human peripheral blood
mononuclear cells (PBMC) prior to administration to the
macaques. Following challenge, blood was collected twice
during the first week, on a weekly basis for the subsequent 3
weeks and monthly thereafter. The animals were euthanized at
different times during the course of infection (in order to
determine viremia and CD4+ T cell loss at various tissues) or
when they developed AIDS. PBMC and plasma were isolated
from each bleed and from the time of death, and were kept
frozen for further analysis.
Determination of CD4+ T cell numbers
CD4+ T lymphocytes in the blood were determined with the
use of an anti-CD4 antibody coupled to PE (clone MT477,
Becton Dickinson). The number of CD3+ T lymphocytes was
determined with the use of an anti-CD3 antibody coupled to
FITC (clone SP34, Becton Dickinson).
Plasma viral load determination
Plasma viremia (RNA copies per ml of blood) was
determined at the Bayer Reference Testing Laboratory (Berkley,
CA). The lower limit of detection is 125 RNA copies per ml.
Determination of viral genotype
To determine the ratio of SHIVSF162P4 and SHIVSF33A
virions circulating in the blood of dually challenged animals, we
employed the heteroduplex mobility assay (HMA) (Delwart et
al., 1993; Harouse et al., 2003). Briefly, viral RNAwas isolated
from plasma of infected animals, using the QIAamp viral RNA
mini kit (QIAGEN, Valencia, CA), DNAase-treated, and
reverse transcribed using oligo (dT)20 and SuperScript III
reverse transcriptase (Invitrogen, Carlsbad, CA). Transcripts
were amplified from the cDNA by PCR with the primers P5
(binds to the C2 region) (Zhu et al., 1993) and PE2 (binds to the
C5 region) (Zhu et al., 2002) using Platinum Taq (Invitrogen).
These primers amplify the SHIVSF162P4 and SHIVSF33A
envelopes with equal efficiency. PCR reactions were carried
out on 2 μl of cDNA using 4 mM Mg2+, 800 nM dNTPs, and
100 nM of each primer. The PCR reaction consisted of
denaturation at 95 °C for 4 min; 25–45 cycles of 95 °C 15 s,
55 °C 30 s, and 72 °C 45 s; and a final extension of 10 min at
72 °C (Fulcher et al., 2004; Zhu et al., 2002). Amplified
products were gel purified using the QIAquick gel extraction kit
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(Invitrogen) and transformed into DH5α-T1 competent cells
(Invitrogen). An additional round of PCR was carried out from
individual clones (up to twenty from each time point) and the
product purified as above. Each sample was heat denatured in
annealing buffer (100 mM NaCl, 10 mM Tris–HCl, pH 7.8, and
2 mM EDTA) at 95 °C for 3 min in the presence of either a ‘P4
probe’ or a ‘33A probe’ and annealed on wet ice. These ‘probes’
correspond to the C2V5 region of SF162 (‘P4 probe’) or
SHIVSF33A (‘33A probe’) envelope gp160. The samples were
then run on 5% polyacrylamide gel at 250 V for 2 h, visualized
by ethidium bromide staining, and the numbers of P4-like and
33A-like clones present at each time point were determined.
Clones that were detected with both the ‘P4 probe’ and ‘33A
probe’ were defined as recombinants (in the C2V5 region)
between the two viruses.
Analysis of sequence diversity
The nucleotide sequences of the above HMA samples or
other C2V5 transcripts amplified by PCR using the primers
ED7 (5′-CTGTTAAATGG CAGTCTAGC) and ED8 (5′-
CACTTCTCCAATTGTCCCTCA) were sequenced using the
primers PE2 (binds to the V5 region of gp120) and M13F (5′-
CAGGAAACAGCTA TGAC-3′) (binds to the TOPO TA
cloning vector pCR 2.1 at the 5′ of the inserted HIV envelope
sequence), respectively. Sequences were analyzed and aligned
using the EditSeq, MegAlign, and SeqMan sequence analysis
programs (DNASTAR).
Generation of mutant envelope glycoproteins
Introduction of the PRH mutations (a S361P in C3, a Q385R
in V4 and a Y425H in C4 regions of gp120) into the plasmid
expressing SF162 envelope gp160 (pEMC* SF162gp160)
(McCaffrey et al., 2004; Saunders et al., 2005) was done
sequentially using three primer sets via PCR and using the
Stratagene Quickchange Mutagenesis Kit according to the
manufacturers protocol.
Determination of anti-HIV envelope binding antibodies
The relative titers of serum antibodies specific for the HIV
envelope were determined longitudinally during immunization
and following SHIV challenge as previously described
(Buckner et al., 2004; Cherpelis et al., 2001). Briefly, soluble
trimeric SF162gp140 (Chiron Corporation, Emeryville, CA)
(0.5 μg/ml in 100 mM NaHCO3, pH 8.5) was used to coat
Immulon 2HB 96-well plates (ThermoLabsystems, Franklin,
MA) (0.1 ml per well) by an overnight incubation at RT.
Following washing with TBS (25 mM Tris/144 mM NaCl, pH:
7.6) the wells were blocked with SuperBlock (SB) (Pierce,
Rockford, IL). Serially diluted (in SB with 0.05% Tween 20)
heat-inactivated (56 °C for 35 min) sera were added to the wells
(0.1 ml per well) for 1 h at 37 °C. Serially diluted pre-
immunization sera from the corresponding animals were used as
negative controls. Unbound antibodies were removed by TBS-washing and the HIV envelope-bound antibodies were detected
with the use of a goat–antihuman IgG coupled to alkaline
phosphatase (Zymed Immunochemicals, South San Francisco,
CA) (1:30,000 dilution in SB and 0.05% Tween 20) (1-h
incubation at 37 °C). The wells were washed with TBS and
substrate for alkaline phosphatase (DAKO Cytomation, Car-
pinteria, CA) was added (50 μl per well) for 1 h at room
temperature. Upon addition of an equal amount of Amplifier
(DAKO Cytomation, Carpinteria, CA) the OD490nm signal
was recorded from each well on a Vmax microplate reader
(Molecular Devises, Sunnyvale, CA). A plot of the OD490 nm
signals versus serum dilution was generated and end-point
antibody titers were determined as the highest post-immuniza-
tion (or post-viral challenge) serum dilution that produces an
OD490 nm signal three times that of the OD490nm produced by
the pre-immunization sera at their lowest dilution.
Cells
The U87 human astroglioma cells expressing CD4 and
CCR5 or CXCR4 were cultured as previously described
(Saunders et al., 2005). TZM-bl cells expressing CD4, CCR5,
and CXCR4 (Wei et al., 2003) and containing an integrated
reporter gene for firefly luciferase under control of an HIV-1
LTR were maintained in DMEM supplemented with 10% FBS,
penicillin (100 U/ml), streptomycin (100 μg/ml), and L-
glutamine (2 mM). Human embryonic kidney (HEK-293T)
cells were maintained in the same growth media as the TZM-bl
cells.
Generation of single-round competent reporter viruses
Preparation of luciferase reporter viruses expressing HIV
envelope glycoproteins derived from SF162, PRH, 89.6, 33A,
HxB2, JRFL, YU2, and ADA and capable of a single round of
replication was carried out as previously described (Saunders
et al., 2005).
Neutralization assays
Sera collected from the animals prior to the initiation of
the immunization protocol (pre-bleeds), following the immu-
nization with recombinant gp140 envelope glycoproteins, and
at various points following infection, were heat inactivated
(1 h at 56 °C), serially diluted in cell medium and incubated
for 1 h at 37 °C with virus. The virion–serum mixture was
then added to TZM-bl cells for 72 h. The supernatant was
removed and the cells were then lysed with 0.1 ml 1× cell
lysis buffer (Cell Culture Lysis Reagent buffer, Promega) and
frozen at −80 °C for 2 h. Following thawing at room
temperature, 0.06 ml from each well was transferred to a
Black Enhanced Binding 96-well solid plate, luciferase
substrate (Promega) was added to each well (0.1 ml per
well) and the relative light units (RLU) associated with each
well were recorded with a Fluoroskan Ascent FL (Thermo-
Labsystems). The percent neutralization was calculated as
follows: (RLU in the wells containing pre-bleeds−RLU in
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RLU in the wells containing pre-bleeds)×100. Single round
competent virus expressing the MuLV envelope was used as a
control for non-specific serum anti-HIV neutralizing activity.
Neutralization of SHIVSF162P4 was tested using a replication
competent virus grown in human PBMC.
Statistical analysis
Total plasma viremia, as well as individual plasma viral
levels of SHIVSF162P4 and SHIVSF33A viruses, during primary
and chronic infection between mock-immunized and immu-
nized animals was compared using t-test analysis. Throughout
the present study, two-tailed P values are cited. A result is
considered significant if the P value is <0.05 (5% level of
significance).
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